Key result
Low-dose endothelin-1 increases normal myocardial blood flow by ~12%, whereas higher doses impair perfusion globally.
Why the study?
Plasma levels of endothelin-1 increase during ischemia and may impair myocardial blood flow, with collateral vessels potentially more sensitive to endothelin-1 effects.
Does endothelin-1 infusion alter myocardial blood flow in normal and collateral-dependent myocardium in a canine model?
Does endothelin-1 infusion alter myocardial blood flow in normal and collateral-dependent myocardium in a canine model?
Moderate elevations of endothelin-1 increase blood flow to normal myocardium but not collateral-dependent myocardium, while high concentrations impair blood flow to both, with prostacyclin playing a key role in blunting vasoconstriction.
Answers are grounded in this paper and cite their sources.
ET-1 effects on MBF differ by zone in canines; leaves open relevance to human collateral-dependent ischemia.
BackgroundPlasma levels of endothelin-1 (ET-1) increase during ischemia and could potentially contribute to impairment of myocardial blood flow (MBF). Because collateral vessels demonstrate enhanced responsiveness to certain vasoconstrictors, blood flow to collateral-dependent myocardium could be particularly sensitive to increases in ET-1 levels.Methods and ResultsStudies were performed in 13 dogs in which collateral vessel development was produced by fluoroscopic embolization of the midleft anterior descending coronary artery with a hollow plug 4 to 6 weeks before the study. MBF was measured with radioactive microspheres at baseline and during 30-minute infusions of ET-1 (1, 10, and 100 ng/min) into the left main coronary artery. Because ET-1 stimulates endothelial prostacyclin release, aortic and coronary sinus levels of ET-1 and 6-keto–prostaglandin F1αwere measured at the end of each infusion. ET-1 increased MBF from 0.82 mL·min−1·g−1at baseline to 0.92 mL·min−1·g−1at 10 ng/min (P<.05), which corresponded to a coronary plasma concentration of 73±16 pg/mL. Blood flow in the collateral zone was less (0.74 mL·min−1·g−1) than in the normal zone (P<.05) and did not increase at an ET-1 dose of 10 ng/min. MBF in the normal and collateral zones significantly decreased when ET-1 was increased to 100 ng/min, corresponding to a coronary sinus concentration of 175±45 pg/mL (P<.05). ET-1 produced dose-related increases in aortic and coronary sinus 6-keto–prostaglandin F1αand the transcoronary difference (P<.05). To assess the importance of prostacyclin in opposing the vasoconstriction produced by ET-1, additional studies were performed after cyclooxygenase blockade with indomethacin. After indomethacin administration, ET-1 (10 ng/min) caused a 120±23% increase in collateral vascular resistance (P<.05) and abolished the vasodilation that this dose produced in the normal zone.ConclusionsBlood flow to normal myocardium is increased at moderate plasma elevations of ET-1, whereas collateral blood flow is unchanged. Only at significantly elevated plasma concentrations of ET-1 is blood flow to normal and collateral-dependent myocardium impaired. Coronary endothelial production of prostacyclin in response to increasing concentrations of ET-1 represents an important means of blunting the vasoconstrictor properties of ET-1 in the canine coronary circulation. Coronary collateral vessels demonstrate a much greater dependence on prostacyclin production in blunting the vasoconstrictor properties of ET-1.
No takes yet. Share an insight, caveat, or question.
Traverse et al. (1996) studied Myocardial ischemia with collateral vessel development (n=13). Endothelin-1 vs. Baseline was evaluated on Myocardial blood flow (MBF) in the normal zone (p=<.05). Endothelin-1 infusion at 10 ng/min increased blood flow to normal myocardium from 0.82 to 0.92 mL/min/g without changing collateral flow, while 100 ng/min impaired flow in both zones.
Synapse has enriched 10 related papers. Consider them for comparative context: